As 2024 comes to a close, here’s a snapshot of what we’ve been up and what’s ahead in 2025 in the pharmaceuticals, biotech products, medical devices, and technologies world.
🌟 2024 Highlights
Healthcare Policy Updates
📌 The HTA Review Report was released in May, featuring 50 recommendations to improve equity, streamline processes, and enhance access to new technologies, including:
- Equitable access for under-represented patient groups.
- Streamlined pathways for timely technology adoption.
- Enhanced real-world data for informed HTA decisions.
📌 New HTA Committee Appointments:
- PBAC Chair: Professor Robyn Ward AM from 5 May 2024.
- MSAC: Professor Jonathan Craig as the Chair of MSAC from 1 April 2024, Professor Kwun Fong as Co-Deputy Chair of MSAC from 1 April 2024 and Associate Professor Sarah Norris as Co-Deputy Chair of MSAC from 1 July 2024.
📌 Horizon Scanning Forum 2024
- Continuing with the theme of the first Horizon Scanning Forum held in 2022 four therapeutic areas where innovative new classes of medicines and treatments stand to disrupt treatment paradigms in Australia and require innovation in system planning were presented and discussed. These were:
-
- Cell and gene therapies,
- Vaccine technology for infectious diseases,
- Novel antimicrobials
- Digital health
-
Industry Engagement – Lucid Health Consulting team
Our team actively participated in leading events locally and globally, such as:
- AusBiotech’s International Women’s Day Luncheon
- 2024PTA-C, the inaugural Pathology Technology Australia Congress
- The Medicines of Tomorrow: Horizon Scanning Forum 2024
- ISPOR Global (Atlanta) and Europe (Barcelona)
- ARCS 2024 Annual Conference, including sponsoring the inaugural CEO Breakfast as well as hosting a booth in the exhibition hall
- The HTA Roadmap – Ideal Outcomes and Reforms workshop
- ISPOR Australia Chapter, Real-World Evidence and HTA Reform Workshop
- AusBiotech 2024, the premier event for Australia’s life sciences community
- Hosted two interns from the USA as part of the nonprofit study abroad and intercultural exchange organization CIEE.
In the News
We were honoured to help our client Tryptamine Therapeutics Limited (ASX:TYP) on the registration and reimbursement strategy for their treatment, TRP-8803 (IV-infused psilocin) globally.
Insights and Research
- Our Director Steve Crowley presented at the Asia-Pacific Value-Based Contracting Webinar Series on transparency in Managed Access Programs.
- Our Director George Papadopoulos, returned to run a session on Healthcare and Market Access Strategy at the CICADA Training Program.
- Our Director George Papadopoulos joined a panel discussing reimbursement in MedTech healthcare and the need for Australia’s HTA system to evolve in response to global trends, at AusMedtech 2024.
- Our Director Michael Aristides co-authored a joint abstract on “The cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy in patients with large B-cell lymphoma in Australia.”
Looking Ahead to 2025, Upcoming Industry Events
- AusMedTech 2025: 7–8 May, ICC, Sydney. Find out more HERE
- ISPOR Global 2025: 13–16 May, Montreal, Canada. Find out more HERE
- ARCS Annual Conference: 3–5 June, ICC, Sydney. Find out more HERE
- ISPOR Europe 2025: 9–12 November, Glasgow, Scotland. Find out more HERE
- Medicines Australia: PharmAus 2025, September 2025, Canberra.
Our Online Tools, Resources and Publications
Explore our tools via our website RESOURCES page. See our 🛠️ PBS Price Calculator | MAOSS Database | easySLR | PBS Calendar (launching soon!)
Missed our 10th Annual Drugs and Devices Australia Reimbursement Update Webinar? The recorded session is available here.
We deeply appreciate your trust and collaboration throughout 2024. Here’s to another year of innovation, progress, and partnership in 2025.
The Lucid Health Consulting Team
Providing expert advice in health economics, pricing a& reimbursement, market access and regulatory affairs in Australia and the Asia-Pacific. At Lucid Health Consulting, we have a proven track record of enabling companies and organisations to optimise the entry of their pharmaceuticals, biotech products, medical devices, and technologies into the Australian market. We understand that getting your products, devices and technologies, successfully into the Australian market matters. That getting the right price for your reimbursements matters. It matters to the patients who need your life-altering products or services at a reasonable price, and it matters to keep your business thriving.
Recent Comments